Prophylactic nimodipine treatment and improvement in hearing outcome after vestibular schwannoma surgery: a combined analysis of a randomized, multicenter, Phase III trial and its pilot study

Author:

Scheller Christian12,Wienke Andreas3,Tatagiba Marcos4,Gharabaghi Alireza4,Ramina Kristofer F.4,Ganslandt Oliver5,Bischoff Barbara5,Zenk Johannes6,Engelhorn Tobias7,Matthies Cordula8,Westermaier Thomas8,Antoniadis Gregor9,Pedro Maria Teresa9,Rohde Veit10,von Eckardstein Kajetan10,Kretschmer Thomas11,Kornhuber Malte12,Steighardt Jörg13,Richter Michael13,Barker Fred G.14,Strauss Christian1

Affiliation:

1. Departments of Neurosurgery and

2. Translational Centre for Regenerative Medicine, University of Leipzig;

3. Institute of Medical Epidemiology, Biostatistics, and Informatics, and

4. Department of Neurosurgery, University of Tübingen;

5. Departments of Neurosurgery,

6. Otorhinolaryngology, Head and Neck Surgery, and

7. Neuroradiology, University of Erlangen-Nuremberg, Erlangen;

8. Department of Neurosurgery, Würzburg University Hospital, Würzburg;

9. Department of Neurosurgery, Bezirkskrankenhaus Günzburg, University of Ulm, Günzburg;

10. Department of Neurosurgery, University of Göttingen; and

11. Department of Neurosurgery, Evangelisches Krankenhaus, University of Oldenburg, Germany; and

12. Neurology,

13. Coordination Centre for Clinical Trials, University of Halle-Wittenberg, Halle (Saale);

14. Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts

Abstract

OBJECTIVEIn clinical routines, neuroprotective strategies in neurosurgical interventions are still missing. A pilot study (n = 30) and an analogously performed Phase III trial (n = 112) pointed to a beneficial effect of prophylactic nimodipine and hydroxyethyl starch (HES) in vestibular schwannoma (VS) surgery. Considering the small sample size, the data from both studies were pooled.METHODSThe patients in both investigator-initiated studies were assigned to 2 groups. The treatment group (n = 70) received parenteral nimodipine (1–2 mg/hour) and HES (hematocrit 30%–35%) from the day before surgery until the 7th postoperative day. The control group (n = 72) was not treated prophylactically. Facial and cochlear nerve functions were documented preoperatively, during the inpatient care, and 1 year after surgery.RESULTSPooled raw data were analyzed retrospectively. Intent-to-treat analysis revealed a significantly lower risk for hearing loss (Class D) 12 months after surgery in the treatment group compared with the control group (OR 0.46, 95% CI 0.22–0.97; p = 0.04). After exclusion of patients with preoperative Class D hearing, this effect was more pronounced (OR 0.38, 95% CI 0.17–0.83; p = 0.016). Logistic regression analysis adjusted for tumor size showed a 4 times lower risk for hearing loss in the treatment group compared with the control group (OR 0.25, 95% CI 0.09–0.63; p = 0.003). Facial nerve function was not significantly improved with treatment. Apart from dose-dependent hypotension (p < 0.001), the study medication was well tolerated.CONCLUSIONSProphylactic nimodipine is safe and may be recommended in VS surgery to preserve hearing. Prophylactic neuroprotective treatment in surgeries in which nerves are at risk seems to be a novel and promising concept.Clinical trial registration no.: DRKS 00000328 (https://drks-neu.uniklinik-freiburg.de/drks_web/)

Publisher

Journal of Neurosurgery Publishing Group (JNSPG)

Subject

Genetics,Animal Science and Zoology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3